Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung

S. Shen, G. L. DeNardo, A. Yuan, D. A. DeNardo, S. J. DeNardo

    Research output: Contribution to journalArticle

    71 Citations (Scopus)

    Abstract

    Yttrium-90 is a promising radionuclide for radioimmunotherapy of cancer because of its energetic beta emissions. Therapeutic management requires quantitative imaging to assess the pharmacokinetics and radiation dosimetry of the 90Y-labeled antibody. Conventional gamma photon imaging methods cannot be easily applied to imaging of 90Y-bremsstrahlung because of its continuous energy spectrum. Methods: The sensitivity, resolution and source- to-background signal ratio (S/B) of the detector system for 90Y- bremsstrahlung were investigated for various collimators and energy windows in order to determine optimum conditions for quantitative imaging. After these conditions were determined, the accuracy of quantitation of 90Y activity in an Alderson abdominal phantom was examined. Results: When the energy-window width was increased, the benefit of increased sensitivity outweighed degradation in resolution and S/B ratio until the manufacturer's energy specifications for the collimator were exceeded. Using the same energy window, we improved resolution and S/B for the medium-energy (ME) collimator when compared to the low-energy, all-purpose (LEAP) collimator, and there was little additional improvement using the high-energy (HE) collimator. Camera sensitivity under tissue equivalent conditions was 4.2 times greater for the LEAP and 1.7 times greater for the ME collimators when compared to the HE collimator. Thus, the best, most practical selections were found to be the ME collimator and an energy window of 55-285 keV. When we used these optimal conditions for image acquisition, the estimation of 90Y activity in organs and tumors was within 15% of the true activities. Conclusions: The results of this study suggest that reasonable accuracy can be achieved in clinical radioimmunotherapy using 90Y-bremsstrahlung quantitation.

    Original languageEnglish (US)
    Pages (from-to)1381-1389
    Number of pages9
    JournalJournal of Nuclear Medicine
    Volume35
    Issue number8
    StatePublished - 1994

    Fingerprint

    Radioimmunotherapy
    Yttrium
    Radionuclide Imaging
    Radiometry
    Photons
    Radioisotopes
    Neoplasms
    Pharmacokinetics
    Antibodies
    Therapeutics

    Keywords

    • antibody
    • bremsstrahlung imaging
    • radiation dosimetry
    • radioimmunotherapy
    • yttrium-90

    ASJC Scopus subject areas

    • Radiological and Ultrasound Technology

    Cite this

    Shen, S., DeNardo, G. L., Yuan, A., DeNardo, D. A., & DeNardo, S. J. (1994). Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung. Journal of Nuclear Medicine, 35(8), 1381-1389.

    Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung. / Shen, S.; DeNardo, G. L.; Yuan, A.; DeNardo, D. A.; DeNardo, S. J.

    In: Journal of Nuclear Medicine, Vol. 35, No. 8, 1994, p. 1381-1389.

    Research output: Contribution to journalArticle

    Shen, S, DeNardo, GL, Yuan, A, DeNardo, DA & DeNardo, SJ 1994, 'Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung', Journal of Nuclear Medicine, vol. 35, no. 8, pp. 1381-1389.
    Shen, S. ; DeNardo, G. L. ; Yuan, A. ; DeNardo, D. A. ; DeNardo, S. J. / Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung. In: Journal of Nuclear Medicine. 1994 ; Vol. 35, No. 8. pp. 1381-1389.
    @article{691dc070edc6490fa499dc3a72df2227,
    title = "Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung",
    abstract = "Yttrium-90 is a promising radionuclide for radioimmunotherapy of cancer because of its energetic beta emissions. Therapeutic management requires quantitative imaging to assess the pharmacokinetics and radiation dosimetry of the 90Y-labeled antibody. Conventional gamma photon imaging methods cannot be easily applied to imaging of 90Y-bremsstrahlung because of its continuous energy spectrum. Methods: The sensitivity, resolution and source- to-background signal ratio (S/B) of the detector system for 90Y- bremsstrahlung were investigated for various collimators and energy windows in order to determine optimum conditions for quantitative imaging. After these conditions were determined, the accuracy of quantitation of 90Y activity in an Alderson abdominal phantom was examined. Results: When the energy-window width was increased, the benefit of increased sensitivity outweighed degradation in resolution and S/B ratio until the manufacturer's energy specifications for the collimator were exceeded. Using the same energy window, we improved resolution and S/B for the medium-energy (ME) collimator when compared to the low-energy, all-purpose (LEAP) collimator, and there was little additional improvement using the high-energy (HE) collimator. Camera sensitivity under tissue equivalent conditions was 4.2 times greater for the LEAP and 1.7 times greater for the ME collimators when compared to the HE collimator. Thus, the best, most practical selections were found to be the ME collimator and an energy window of 55-285 keV. When we used these optimal conditions for image acquisition, the estimation of 90Y activity in organs and tumors was within 15{\%} of the true activities. Conclusions: The results of this study suggest that reasonable accuracy can be achieved in clinical radioimmunotherapy using 90Y-bremsstrahlung quantitation.",
    keywords = "antibody, bremsstrahlung imaging, radiation dosimetry, radioimmunotherapy, yttrium-90",
    author = "S. Shen and DeNardo, {G. L.} and A. Yuan and DeNardo, {D. A.} and DeNardo, {S. J.}",
    year = "1994",
    language = "English (US)",
    volume = "35",
    pages = "1381--1389",
    journal = "Journal of Nuclear Medicine",
    issn = "0161-5505",
    publisher = "Society of Nuclear Medicine Inc.",
    number = "8",

    }

    TY - JOUR

    T1 - Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung

    AU - Shen, S.

    AU - DeNardo, G. L.

    AU - Yuan, A.

    AU - DeNardo, D. A.

    AU - DeNardo, S. J.

    PY - 1994

    Y1 - 1994

    N2 - Yttrium-90 is a promising radionuclide for radioimmunotherapy of cancer because of its energetic beta emissions. Therapeutic management requires quantitative imaging to assess the pharmacokinetics and radiation dosimetry of the 90Y-labeled antibody. Conventional gamma photon imaging methods cannot be easily applied to imaging of 90Y-bremsstrahlung because of its continuous energy spectrum. Methods: The sensitivity, resolution and source- to-background signal ratio (S/B) of the detector system for 90Y- bremsstrahlung were investigated for various collimators and energy windows in order to determine optimum conditions for quantitative imaging. After these conditions were determined, the accuracy of quantitation of 90Y activity in an Alderson abdominal phantom was examined. Results: When the energy-window width was increased, the benefit of increased sensitivity outweighed degradation in resolution and S/B ratio until the manufacturer's energy specifications for the collimator were exceeded. Using the same energy window, we improved resolution and S/B for the medium-energy (ME) collimator when compared to the low-energy, all-purpose (LEAP) collimator, and there was little additional improvement using the high-energy (HE) collimator. Camera sensitivity under tissue equivalent conditions was 4.2 times greater for the LEAP and 1.7 times greater for the ME collimators when compared to the HE collimator. Thus, the best, most practical selections were found to be the ME collimator and an energy window of 55-285 keV. When we used these optimal conditions for image acquisition, the estimation of 90Y activity in organs and tumors was within 15% of the true activities. Conclusions: The results of this study suggest that reasonable accuracy can be achieved in clinical radioimmunotherapy using 90Y-bremsstrahlung quantitation.

    AB - Yttrium-90 is a promising radionuclide for radioimmunotherapy of cancer because of its energetic beta emissions. Therapeutic management requires quantitative imaging to assess the pharmacokinetics and radiation dosimetry of the 90Y-labeled antibody. Conventional gamma photon imaging methods cannot be easily applied to imaging of 90Y-bremsstrahlung because of its continuous energy spectrum. Methods: The sensitivity, resolution and source- to-background signal ratio (S/B) of the detector system for 90Y- bremsstrahlung were investigated for various collimators and energy windows in order to determine optimum conditions for quantitative imaging. After these conditions were determined, the accuracy of quantitation of 90Y activity in an Alderson abdominal phantom was examined. Results: When the energy-window width was increased, the benefit of increased sensitivity outweighed degradation in resolution and S/B ratio until the manufacturer's energy specifications for the collimator were exceeded. Using the same energy window, we improved resolution and S/B for the medium-energy (ME) collimator when compared to the low-energy, all-purpose (LEAP) collimator, and there was little additional improvement using the high-energy (HE) collimator. Camera sensitivity under tissue equivalent conditions was 4.2 times greater for the LEAP and 1.7 times greater for the ME collimators when compared to the HE collimator. Thus, the best, most practical selections were found to be the ME collimator and an energy window of 55-285 keV. When we used these optimal conditions for image acquisition, the estimation of 90Y activity in organs and tumors was within 15% of the true activities. Conclusions: The results of this study suggest that reasonable accuracy can be achieved in clinical radioimmunotherapy using 90Y-bremsstrahlung quantitation.

    KW - antibody

    KW - bremsstrahlung imaging

    KW - radiation dosimetry

    KW - radioimmunotherapy

    KW - yttrium-90

    UR - http://www.scopus.com/inward/record.url?scp=0028068643&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0028068643&partnerID=8YFLogxK

    M3 - Article

    C2 - 8046498

    AN - SCOPUS:0028068643

    VL - 35

    SP - 1381

    EP - 1389

    JO - Journal of Nuclear Medicine

    JF - Journal of Nuclear Medicine

    SN - 0161-5505

    IS - 8

    ER -